Oxiblume:CoQ10 (Ralivia) Therapy for Benign Prostatic Hyperplasia:
Oxiblume:CoQ10 (Ralivia) Therapy for Benign Prostatic Hyperplasia: a Double-blind Placebo-controlled Randomized Clinical Trial Assessing Treatment Efficacy and Safety.
Objectives of the study
The aim of the study is to investigate and compare the treatment efficacy and safety of Oxiblume:CoQ10 (Ralivia) therapy vs placebo for BPH patients
Study center
The study will be coordinated by the research office of 1st Urology Department, G. Gennimatas Hospital, Aristotle University of Thessaloniki, Greece. The research office will also support the project (logistics, quality control, management, data acquisition, publications).
Patients visits will be carried out in the BPH Research Unit of the 1st Urology Department, G. Gennimatas Hospital, Aristotle University of Thessaloniki, Greece.
Laboratory tests of all patients will be performed at the same microbiology laboratory.
Study population A total of 100 patients (50 in Group A and 50 in Group B) with BPH diagnosis will participate in this study.
Study design Double-blind placebo-controlled randomized clinical trial
Zero hypothesis (H0) and alternative hypothesis (H1):
(H0): Group A demonstrates similar efficacy compared to Group B for the treatment of BPH patients.
(H1): Group A demonstrates greater or decreased efficacy compared to Group B for the treatment of BPH patients.
Study endpoints Primary endpoint: The difference between the Group A and Group B in the change of IPSS score from baseline to 12 weeks after treatment initiation.
Secondary endpoints:
- Adverse events rate in all patients during study period.
- The difference between the Group A and Group B in the change of the IPSS score from baseline to 6 weeks after treatment initiation.
The difference between the Group A and Group B in the change of the following parameters from baseline to 6 and 12 weeks after treatment initiation
- Qmax value
- Prostate volume
- Post void residual
- IIEF-ED score
- Psa value
- TNFa, IL 6 values
Treatment Visits :
Patients accordingly to which group they will be randomized will receive:
- Active treatment (Ralivia) Group : 1 pill of Ralivia per os/day for a 3-month period
- Placebo Group : 1 placebo pill per os/day for a 3-month period
Adverse events will be reported.
FU Visit 1: 6 weeks after treatment initiation IPSS, IIEF-ED questionnaires will be answered. Prostate and Urinary Bladder ultrasound will be conducted pre- and post-void. Uroflowmetry will be conducted. Adverse events will be reported.
PSA TNFa, IL 1β, IL 6, IL 10 will be measured through blood test.
FU Visit 2: 12 weeks after treatment initiation IPSS, IIEF-ED questionnaires will be answered. Prostate and Urinary Bladder ultrasound will be conducted pre- and post-void. Uroflowmetry will be conducted. Adverse events will be reported.
DRE will be performed . PSA TNFa, IL 6 will be measured through blood test.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Thessaloniki, Grécia, 54636
- Recrutamento
- G.Gennimatas General Hospital
-
Contato:
- IOANNIS MYKONIATIS, Ass.Professor
- Número de telefone: +30 6936975862
- E-mail: g_mikoniatis@hotmail.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Participant must be between 50 and 80 years old.
- Participant has signed and dated the appropriate Informed Consent document.
- International Prostate Symptom Score (IPSS) ≥8 and ≤30
- Prostate volume ≥30gram and ≤80gram
- Peak urinary flow rate (Qmax) ≥5 ml/sec and ≤15ml/sec
- Post void residual volume ≤150ml
Exclusion Criteria:
- Current or recurrent urinary tract infection (UTI), prostatitis, gross hematuria (blood in urine without a known cause), or a history of urinary retention.
- Participant has a history of prostate, bladder or urethral cancer.
- Participant has undergone pelvic radiation or systemic chemotherapy.
- Participant has undergone intravesical chemotherapy.
- Participant has unilateral orchialgia without pelvic symptoms, active urethral stricture or bladder stones, or any other urological condition (except from BPH) associated with LUTS, any neurological disease or disorder affecting the bladder.
- Participant has undergone prostate surgery
- Participant with penile or urinary sphincter implants.
- Diagnosed neurological conditions known to affect bladder function (e.g., multiple sclerosis, Parkinson's disease, or neurogenic bladder).
- Significant medical conditions (e.g., unstable cardiac arrhythmias, uncontrolled diabetes, severe renal impairment) that pose an unreasonable risk to the patient or might interfere with study results.
- Participant has been diagnosed with cancer during the last 5 years or had any surgery in the pelvis.
- Participant has a neurological impairment or psychiatric disorder preventing his understanding of consent and his ability to comply with the protocol.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Group A
Patients of the Active Group will receive 1 pill of Ralivia per os/day for a 3-month period
|
1 pill of Ralivia per os/day for a 3-month period
|
|
Comparador de Placebo: Group B
Patients of the Placebo Group will receive 1 placebo pill per os/day for a 3-month period
|
1 placebo pill per os/day for a 3-month period
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
The difference between the Group A and Group B in the change of IPSS score at 12 weeks after treatment initiation.
Prazo: "From enrollment to 12 weeks after treatment initiation "
|
"From enrollment to 12 weeks after treatment initiation "
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
|---|---|
|
The difference between the Group A and Group B in the change of the IPSS score from baseline to 6 weeks after treatment initiation.
Prazo: From enrollment to 6 weeks
|
From enrollment to 6 weeks
|
|
The difference between the Group A and Group B in the change of Qmax value from baseline to 6 and 12 weeks after treatment initiation.
Prazo: From enrollment to 6 and 12 weeks
|
From enrollment to 6 and 12 weeks
|
|
The difference between the Group A and Group B in the change of prostate volume from baseline to 6 and 12 weeks after treatment initiation.
Prazo: From enrollment to 6 and 12 weeks
|
From enrollment to 6 and 12 weeks
|
|
The difference between the Group A and Group B in the change of post void residual (PVR) from baseline to 6 and 12 weeks after treatment initiation.
Prazo: From enrollment to 6 and 12 weeks
|
From enrollment to 6 and 12 weeks
|
|
The difference between the Group A and Group B in the change of International Index of Erectile Function -Erectile Domaine (IIEF-ED) score from baseline to 6 and 12 weeks after treatment initiation.
Prazo: From enrollment to 6 and 12 weeks
|
From enrollment to 6 and 12 weeks
|
|
The difference between the Group A and Group B in the change of PSA value from baseline to 6 and 12 weeks after treatment initiation.
Prazo: From enrollment to 6 and 12 weeks
|
From enrollment to 6 and 12 weeks
|
|
The difference between the Group A and Group B in the change of TNFa and IL6 value from baseline to 6 and 12 weeks after treatment initiation.
Prazo: From enrollment to 6 and 12 weeks
|
From enrollment to 6 and 12 weeks
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- Ralivia_BPH- 22/5/26
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .